• H.R. 2853 BLOCKING Act of 2021 (All sections of full text). S. 2910, Expanding Access to Low-Cost Generics Act of 2021 (All sections of full text). Discussions regarding S. 3799, PREVENT Pandemics Act of 2022. Discussions regarding the reauthorization of Generic Drug User Fee Amendments included in P.L.117-95, Extension of Continuing Appropriations Act. Discussions regarding improved education about digital health care. Monitored the implementation of P.L. 117-169, Inflation Reduction Act of 2022. Monitored the implementation of P.L.117-7, To prevent across-the-board direct spending cuts, and for other purposes. Monitored Medicare and prescription drug changes. Monitored discussions related to mental health legislation.
• Discussions related to FDA 'skinny labelling' issue. Monitored HR 7377, Modernizing Therapeutic Equivalence Rating Determination Act. Monitored S. 1463, Modernizing Therapeutic Equivalence Rating Determination Act.

Duration: January 25, 2021 to February 1, 2023

General Issues: Health Issues, Copyright/Patent/Trademark

Spending: about $610,000 (But it's complicated. Here's why.)

It can be tricky to figure out how much an organization spent on a particular lobbying engagement. The law only requires lobbyists to report the amount they were paid for federal lobbying each quarter rounded to the nearest $10,000—and if it's less than $3,000 in a given quarter (or less than $13,000 for organizations with in-house lobbyists), they don't have to disclose it at all. Plus, some organizations include spending that doesn’t belong in the report—for instance, money spent lobbying state governments or other legal work.

Agencies lobbied since 2021: House of Representatives, U.S. Senate, Centers For Medicare and Medicaid Services (CMS), White House Office, Commerce - Dept of (DOC), Vice President of the U.S.